Increased metastasis with loss of E2F2 in Myc-driven tumors
PDF | HTML | Supplementary Files | How to cite
Metrics: PDF 2193 views | HTML 2845 views | ?
Inez Yuwanita1, Danielle Barnes1, Michael D. Monterey1, Sandra O'Reilly1, Eran R. Andrechek1
1Department of Physiology, Michigan State University, East Lansing, MI48824, Michigan, USA
Eran R. Andrechek, e-mail: [email protected]
Keywords: MMTV-Myc, metastasis, E2F transcription factors, PTPRD, gene expression
Received: June 01, 2015 Accepted: September 30, 2015 Published: October 13, 2015
In human breast cancer, mortality is associated with metastasis to distant sites. Therefore, it is critical to elucidate the biological mechanisms that underlie tumor progression and metastasis. Using signaling pathway signatures we previously predicted a role for E2F transcription factors in Myc induced tumors. To test this role we interbred MMTV-Myc transgenic mice with E2F knockouts. Surprisingly, we observed that the loss of E2F2 sharply increased the percentage of lung metastasis in MMTV-Myc transgenic mice. Examining the gene expression profile from these tumors, we identified genetic components that were potentially involved in mediating metastasis. These genes were filtered to uncover the genes involved in metastasis that also impacted distant metastasis free survival in human breast cancer. In order to elucidate the mechanism by which E2F2 loss enhanced metastasis we generated knockdowns of E2F2 in MDA-MB-231 cells and observed increased migration in vitro and increased lung colonization in vivo. We then examined genes that were differentially regulated between tumors from MMTV-Myc, MMTV-Myc E2F2−/−, and lung metastases samples and identified PTPRD. To test the role of PTPRD in E2F2-mediated breast cancer metastasis, we generated a knockdown of PTPRD in MDA-MB-231 cells. We noted that decreased levels of PTPRD resulted in decreased migration in vitro and decreased lung colonization in vivo. Taken together, these data indicate that E2F2 loss results in increased metastasis in breast cancer, potentially functioning through a PTPRD dependent mechanism.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.